المؤلفون: Mona Aflaki, Alexandria Flannery, João Pedro Ferreira, Matthew Pellan Cheng, Nadine Kronfli, Ariane Marelli, Faiez Zannad, James Brophy, Jon Afillalo, Thao Huynh, Nadia Giannetti, Amal Bessissow, Justin A. Ezekowitz, Renato D. Lopes, Andrew P. Ambrosy, Morgan Craig, Abhinav Sharma

المصدر: Trials, Vol 22, Iss 1, Pp 1-3 (2021)

مصطلحات موضوعية: COVID-19, Randomised controlled trial, Protocol, SARS- CoV2, RAAS inhibitor, ACE2, Medicine (General), R5-920

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1745-6215Test

الوصول الحر: https://doaj.org/article/fec9772059094f5ca0e86efee8399ac8Test

المؤلفون: Abhinav Sharma, Nadia Giannetti, James M. Brophy, Ariane Marelli, Andrew P. Ambrosy, Alexandria Flannery, Jon Afillalo, Morgan Craig, Faiez Zannad, Justin A. Ezekowitz, João Pedro Ferreira, Renato D. Lopes, Mona Aflaki, Matthew P. Cheng, Nadine Kronfli, Thao Huynh, Amal Bessissow

المساهمون: BOZEC, Erwan, Division of Internal Medicine, McGill University Health Centre, McGill University, McGill University Health Center [Montreal] (MUHC), Division of Cardiology, McGill University Health Centre, McGill University, DREAM-CV Lab, McGill University = Université McGill [Montréal, Canada], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Division of Infectious Disease, McGill University Health Centre, McGill University, Division of Cardiology, Jewish General Hospital, McGill University, University of Alberta, Duke Clinical Research Institute, Duke University, Department of Cardiology, Kaiser Permanente San Francisco Medical Center, Division of Research, Kaiser Permanente Northern California, Sainte-Justine University Hospital Research Centre and Department of Mathematics and Statistics, Université de Montréal, This study is sponsored by the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) and the McGill University Health Centre Division ofCardiology, DREAM-CV Lab, McGill University Health Centre Research Institute, McGill University, Canadian VIGOUR Centre, University of Alberta

المصدر: Trials
Trials, BioMed Central, 2021, 22 (1), pp.115. ⟨10.1186/s13063-021-05080-4⟩
Trials, Vol 22, Iss 1, Pp 1-3 (2021)

مصطلحات موضوعية: Male, Medicine (miscellaneous), ACE2, Angiotensin-Converting Enzyme Inhibitors, 030204 cardiovascular system & hematology, Polymerase Chain Reaction, SARS- CoV2, law.invention, Renin-Angiotensin System, Study Protocol, 0302 clinical medicine, Patient Admission, Randomized controlled trial, law, Clinical endpoint, Protocol, Medicine, Pharmacology (medical), 030212 general & internal medicine, 10. No inequality, Randomized Controlled Trials as Topic, Aged, 80 and over, Randomised controlled trial, lcsh:R5-920, Middle Aged, Cardiovascular disease, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Intensive Care Units, Treatment Outcome, Inclusion and exclusion criteria, Female, Angiotensin-Converting Enzyme 2, RAAS inhibitor, lcsh:Medicine (General), Adult, medicine.medical_specialty, Canada, Antagonists & inhibitors, Randomization, Adolescent, Context (language use), 03 medical and health sciences, Young Adult, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, ACE inhibitor, Humans, Mortality, Antihypertensive Agents, Aged, business.industry, SARS-CoV-2, COVID-19, Discontinuation, COVID-19 Drug Treatment, Clinical trial, Withholding Treatment, Emergency medicine, business, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50594e8e12fc222d52699550ff522561Test
https://hal.univ-lorraine.fr/hal-03136429/documentTest